IL274585B2 - Deuterated d-serine analogs and their uses - Google Patents

Deuterated d-serine analogs and their uses

Info

Publication number
IL274585B2
IL274585B2 IL274585A IL27458520A IL274585B2 IL 274585 B2 IL274585 B2 IL 274585B2 IL 274585 A IL274585 A IL 274585A IL 27458520 A IL27458520 A IL 27458520A IL 274585 B2 IL274585 B2 IL 274585B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutical composition
formula
serine
deuterium
Prior art date
Application number
IL274585A
Other languages
English (en)
Hebrew (he)
Other versions
IL274585B1 (en
IL274585A (en
Original Assignee
Concert Pharmaceuticals Inc
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc, Sun Pharmaceutical Ind Inc filed Critical Concert Pharmaceuticals Inc
Publication of IL274585A publication Critical patent/IL274585A/en
Publication of IL274585B1 publication Critical patent/IL274585B1/en
Publication of IL274585B2 publication Critical patent/IL274585B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL274585A 2017-11-22 2018-11-21 Deuterated d-serine analogs and their uses IL274585B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US201862755157P 2018-11-02 2018-11-02
PCT/US2018/062263 WO2019104179A1 (en) 2017-11-22 2018-11-21 Deuterated analogs of d-serine and uses thereof

Publications (3)

Publication Number Publication Date
IL274585A IL274585A (en) 2020-06-30
IL274585B1 IL274585B1 (en) 2025-09-01
IL274585B2 true IL274585B2 (en) 2026-01-01

Family

ID=64755715

Family Applications (2)

Application Number Title Priority Date Filing Date
IL274585A IL274585B2 (en) 2017-11-22 2018-11-21 Deuterated d-serine analogs and their uses
IL322463A IL322463A (en) 2017-11-22 2018-11-21 Deuterated d-serine analogs and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL322463A IL322463A (en) 2017-11-22 2018-11-21 Deuterated d-serine analogs and their uses

Country Status (13)

Country Link
US (4) US20200368193A1 (https=)
EP (2) EP3713557B1 (https=)
JP (3) JP7518765B2 (https=)
KR (1) KR102916897B1 (https=)
CN (1) CN111491629A (https=)
AU (2) AU2018371784B2 (https=)
BR (1) BR112020010156A2 (https=)
CA (1) CA3082834A1 (https=)
IL (2) IL274585B2 (https=)
MX (1) MX2020005336A (https=)
PL (1) PL3713557T3 (https=)
TW (1) TWI886093B (https=)
WO (1) WO2019104179A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491629A (zh) * 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
WO2020206367A1 (en) * 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
WO2020243638A1 (en) * 2019-05-30 2020-12-03 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
EP4076461B1 (en) * 2019-12-19 2026-01-28 Intra-Cellular Therapies, Inc. Lumateperone for use in schizophrenia treatment
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
US20020035145A1 (en) * 1998-04-14 2002-03-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20140187597A1 (en) * 2003-02-06 2014-07-03 Sarah Herzog Memorial Hospital Ezrath Nashim Association Pharmaceutical compositions for the treatment of movement disorders
US20170326137A1 (en) * 2013-05-28 2017-11-16 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US5845286A (en) 1996-12-24 1998-12-01 Colizza; Vincent Date value reduction system
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2602626A1 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
CN111491629A (zh) * 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
WO2020243650A1 (en) 2019-05-29 2020-12-03 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
US20020035145A1 (en) * 1998-04-14 2002-03-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20140187597A1 (en) * 2003-02-06 2014-07-03 Sarah Herzog Memorial Hospital Ezrath Nashim Association Pharmaceutical compositions for the treatment of movement disorders
US20170326137A1 (en) * 2013-05-28 2017-11-16 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B. SVANTE AXELSSON ET AL:, VERSATILE SYNTHESIS OF STEREOSPECIFICALLY LABELLED D-AMINO ACIDS VIA LABELLED, 1 January 1994 (1994-01-01) *
CONCERT PHARMACEUTICALS ET AL:, PRECISION DEUTERIUM CHEMISTRY BACKGROUNDER, 31 December 2007 (2007-12-31) *
FOSTER A B:, DEUTERIUM ISOTOPE EFFECTS IN THE METABOLISM OF DRUGS AND XENOBIOTICS: IMPLICATIONS FOR DRUG DESIGN, 1 January 1985 (1985-01-01) *
KANTROWITZ J T ET AL:, HIGH DOSE D-SERINE IN THE TREATMENT OF SCHIZOPHRENIA, 1 August 2010 (2010-08-01) *
KOHNOSUKE KINOSHITA ET AL:, A SURROGATE ANALYTE METHOD TO DETERMINE D-SERINE IN MOUSE BRAIN USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, 1 January 2013 (2013-01-01) *
SCOTT L. HARBESON ET AL:, DEUTERIUM MEDICINAL CHEMISTRY: A NEW APPROACH TO DRUG DISCOVERY AND DEVELOPMENT, 1 May 2014 (2014-05-01) *
TOMOKAZU ITO ET AL:, ROLE OF ZINC ION FOR CATALYTIC ACTIVITY IN D-SERINE DEHYDRATASE FROM SACCHAROMYCES?CEREVISIAE : ROLE OF ZINC IN EUKARYOTIC D-SERINE DEHYDRATASE, 1 February 2012 (2012-02-01) *

Also Published As

Publication number Publication date
AU2025200345A1 (en) 2025-02-13
US10668036B2 (en) 2020-06-02
JP2023123476A (ja) 2023-09-05
CA3082834A1 (en) 2019-05-31
US20200390732A1 (en) 2020-12-17
US20200368193A1 (en) 2020-11-26
JP7733058B2 (ja) 2025-09-02
KR20200103662A (ko) 2020-09-02
US20190328692A1 (en) 2019-10-31
IL274585B1 (en) 2025-09-01
KR102916897B1 (ko) 2026-01-26
JP2021504326A (ja) 2021-02-15
MX2020005336A (es) 2020-08-13
US12029712B2 (en) 2024-07-09
JP7518765B2 (ja) 2024-07-18
US20250000830A1 (en) 2025-01-02
EP4560024A2 (en) 2025-05-28
TW201924668A (zh) 2019-07-01
WO2019104179A1 (en) 2019-05-31
IL274585A (en) 2020-06-30
CN111491629A (zh) 2020-08-04
BR112020010156A2 (pt) 2020-11-10
PL3713557T3 (pl) 2025-09-22
EP3713557B1 (en) 2025-03-12
IL322463A (en) 2025-09-01
EP4560024A3 (en) 2025-08-20
EP3713557A1 (en) 2020-09-30
AU2018371784A1 (en) 2020-05-28
AU2018371784B2 (en) 2024-10-17
WO2019104179A4 (en) 2019-08-01
JP2025138735A (ja) 2025-09-25
TWI886093B (zh) 2025-06-11

Similar Documents

Publication Publication Date Title
US20250000830A1 (en) Deuterated analogs of d-serine and uses thereof
JP7475055B2 (ja) （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法
US20110212944A1 (en) 2-oxo-1-pyrrolidine derivatives
US20120071554A1 (en) Deuterated 2-propylpentanoic acid compounds
US20220313640A1 (en) Deuterated analogs of d-serine and uses thereof
EA050051B1 (ru) Дейтерированные аналоги d-серина и их применение
US20220218641A1 (en) Methods of treatment with deuterated analogs of d-serine
US10843993B2 (en) Deuterated idebenone
EP4304655A1 (en) Fatty acid-bifunctional degrader conjugates and their methods of use
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
JP2025535312A (ja) フェネチルアミンおよびカチノンならびにそれらの立体異性体およびそれらの前駆体の調製
WO2025223511A1 (zh) 一类苯甲酰基甘氨酸衍生物及其制备方法和应用
BR112020022885B1 (pt) Processo para preparar um composto e composto